Ulcerative proctitis: an update on the pharmacotherapy and management

Bibliography

• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012;380:1606-19
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The montreal classification of inflammatory bowel disease. controversies. consensus. and implications. Gut 2006;55:749-53
   PubMed Web of Science ®Google Scholar
• D’Haens G, Geboes K, Peeters M, et al. Patchy cecal inflammation associated with distal ulcerative colitis. a prospective endoscopic study. Am J Gastroenterol 1997;92:1275-9
   PubMed Web of Science ®Google Scholar
• Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases. up or down? World J Gastroenterol 2006;12:6102-8
   PubMed Web of Science ®Google Scholar
• Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis. and early disease course in inflammatory bowel diseases in Western Hungary. 2002-2006. Inflamm Bowel Dis 2011;17(2558):65
   Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis. a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000;95:469-73
   PubMed Web of Science ®Google Scholar
• Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol 2014;49:177-83
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6
   PubMed Web of Science ®Google Scholar
• Ayres RC, Gillen CD, Walmsley RS, et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996;8:555-8
   PubMedGoogle Scholar
• Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004;10:731-6
   PubMed Web of Science ®Google Scholar
• Ford AC, Khan KJ, Sandborn WJ, et al. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:513-19
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95. quiz e14-5
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109. e1
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-32
   PubMed Web of Science ®Google Scholar
• Brunner M, Vogelsang H, Greinwald R, et al. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther 2005;22:463-70
   PubMed Web of Science ®Google Scholar
• Cortot A, Maetz D, Degoutte E, et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008;103:3106-14
   PubMedGoogle Scholar
• Desreumaux P, Ghosh S. Review article. mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006;24(Suppl 1):2-9
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9:293-300
   PubMed Web of Science ®Google Scholar
• Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513-22
   PubMed Web of Science ®Google Scholar
• Andus T, Kocjan A, Muser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010;16:1947-56
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nishino H, Sameshima Y, et al. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo-controlled study. Aliment Pharmacol Ther 2013;38:264-73
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-7
   PubMed Web of Science ®Google Scholar
• Hebden JM, Blackshaw PE, Perkins AC, et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2000;14:155-61
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543
   PubMed Web of Science ®Google Scholar
• Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21:827-34
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43. e1-3
   PubMedGoogle Scholar
• Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71
   PubMed Web of Science ®Google Scholar
• Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-62
   PubMed Web of Science ®Google Scholar
• Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361-6
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998;115:525-32
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39:329-37
   PubMedGoogle Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-53
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;2:375-8
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13
   PubMed Web of Science ®Google Scholar
• Seibold F, Fournier N, Beglinger C, et al. Topical therapy is underused in patients with ulcerative colitis. J Crohns Colitis 2014;8:56-63
   PubMed Web of Science ®Google Scholar
• Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007;13:1244-9
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5
   PubMed Web of Science ®Google Scholar
• Park SK, Yang SK, Ye BD, et al. The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis. Scand J Gastroenterol 2013;48:1386-93
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400. e3
   PubMed Web of Science ®Google Scholar
• Bouguen G, Roblin X, Bourreille A, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010;31:1178-85
   Google Scholar
• Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-20
   PubMed Web of Science ®Google Scholar
• van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009;15:193-8
   PubMed Web of Science ®Google Scholar
• Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther 2013;37:129-36
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Nagy F, et al. Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. Am J Gastroenterol 2009;104:1857-8
   Google Scholar
• Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005;50:2323-9
   PubMed Web of Science ®Google Scholar
• Bolin TD, Wong S, Crouch R, et al. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol 2009;104:2476-82
   Google Scholar
• Bageacu S, Coatmeur O, Lemaitre JP, et al. Appendicectomy as a potential therapy for refractory ulcerative proctitis. Aliment Pharmacol Ther 2011;34:257-8
   Google Scholar
• Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-7
   PubMed Web of Science ®Google Scholar
• Kono T, Nomura M, Kasai S, et al. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001;96:793-7
   PubMed Web of Science ®Google Scholar
• Arlander E, Ost A, Stahlberg D, et al. Ropivacaine gel in active distal ulcerative colitis and proctitis – a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996;10:73-81
   PubMed Web of Science ®Google Scholar
• Joos S, Rosemann T, Szecsenyi J, et al. Use of complementary and alternative medicine in Germany-a survey of patients with inflammatory bowel disease. BMC Complement Altern Med 2006;6:19
   PubMedGoogle Scholar
• Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:854-63
   PubMed Web of Science ®Google Scholar
• Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005;50:2191-3
   PubMed Web of Science ®Google Scholar
• Brunel M, Penna C, Tiret E, et al. Restorative proctocolectomy for distal ulcerative colitis. Gut 1999;45:542-5
   PubMedGoogle Scholar
• Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004;99:1527-31
   PubMedGoogle Scholar
• Wu B, Lian L, Li Y, et al. Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. Inflamm Bowel Dis 2013;19:404-10
   PubMed Web of Science ®Google Scholar
• Richter JM, Kushkuley S, Barrett JA, et al. Treatment of new-onset ulcerative colitis and ulcerative proctitis. a retrospective study. Aliment Pharmacol Ther 2012;36:248-56
   Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544
   PubMedGoogle Scholar
• Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95:1749-54
   PubMed Web of Science ®Google Scholar
• d’Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998;93:799-803
   Google Scholar
• Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998;42:195-9
   PubMed Web of Science ®Google Scholar
• d’Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7
   PubMedGoogle Scholar
• Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as Maintenance Treatment for Ulcerative Colitis in Remission. Lancet 1965;1:188-9
   PubMed Web of Science ®Google Scholar
• Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982;284:1291-2
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
   PubMed Web of Science ®Google Scholar
• Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
   PubMed Web of Science ®Google Scholar
• Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45
   PubMed Web of Science ®Google Scholar
• Lopez A, Peyrin-Biroulet L. 5-Aminosalicylic acid and chemoprevention: does it work? Dig Dis 2013;31:248-53
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1-33
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-36
   PubMed Web of Science ®Google Scholar
• Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15:935-50
   PubMed Web of Science ®Google Scholar